Robert A. Figlin

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 3999: Pan-cancer prediction of response to immune checkpoint blockade from histopathology

  Cancer Research · 2026-04-03

• DZ-1-artesunate conjugate induces mitochondria-mediated, reactive oxygen species-dependent apoptosis in colorectal cancer tumoroids

  Frontiers in Pharmacology · 2026-03-20

• A model psychosocial-spiritual oncology and cancer supportive care services program: Framework and implementation

  Journal of Psychosocial Oncology · 2026-01-18

• 1113 TIME_ACT: pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathologyPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-06-30

• A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

  Journal of Clinical Oncology · 2025-02-10 · 5 citations

• A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).

  Journal of Clinical Oncology · 2025-02-10

• Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2025-01-01 · 21 citations